Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transdermal Drug Delivery Systems

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Oral Drug Delivery Systems: Introduction

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

Drugs Acting on Autonomic Ganglia: Stimulants

Drugs Acting on Autonomic Ganglia: Stimulants

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study.

Sleep medicine·2025

Same author

COVID-19 Reveals Opportunities for Better Care of Stroke Patients–Direct Transfer to Postacute Rehabilitation, Reduction in Length of Stay, and Treatment Outcomes.

Deutsches Arzteblatt international·2021

Same author

Enhancing medication therapy in Parkinson's disease by establishing an interprofessional network including pharmacists.

International journal of clinical pharmacy·2021

Same author

Insomnia in neurological diseases.

Neurological research and practice·2021

Same author

Quickcard-Based Approach to Guiding Specific Nonpharmacological Treatments in a German Parkinson's Network.

Journal of clinical medicine·2020

Same author

Processing of a Subliminal Rebus during Sleep: Idiosyncratic Primary versus Secondary Process Associations upon Awakening from REM- versus Non-REM-Sleep.

Frontiers in psychology·2017

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

Rotigotine transdermal system: a short review.

Sabine Bunten¹, Svenja Happe

¹Department of Clinical Neurophysiology, Klinikum Bremen-Ost/University of Göttingen, Germany.

Neuropsychiatric Disease and Treatment

|May 5, 2009

Summary

Rotigotine (Neupro) is a once-daily dopamine agonist patch for Parkinson's disease and restless legs syndrome. This review covers its characteristics, effectiveness, and rationale for use.

Keywords:

Parkinson’s disease restless legs syndrome rotigotine transdermal patch

More Related Videos

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation

Published on: January 3, 2020

Related Experiment Videos

Last Updated: Jun 23, 2026

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation

Updated Technique for Reliable, Easy, and Tolerated Transcranial Electrical Stimulation Including Transcranial Direct Current Stimulation

Published on: January 3, 2020

Area of Science:

Pharmacology and Therapeutics
Neurology
Drug Delivery Systems

Background:

Rotigotine (Neupro) is a non-ergoline dopamine agonist delivered via a transdermal patch.
It offers once-daily application for patient convenience.
Currently approved for early Parkinson's disease (PD) monotherapy.

Purpose of the Study:

To provide a comprehensive overview of rotigotine.
To discuss its physical, chemical, and pharmaceutical properties.
To review pharmacokinetic and pharmacodynamic data, including interactions and adverse events.

Main Methods:

Literature review of clinical trials and scientific data.
Analysis of rotigotine's physicochemical and pharmacokinetic profiles.
Evaluation of its efficacy and safety in treating PD and restless legs syndrome (RLS).

Main Results:

Rotigotine demonstrates efficacy in early and advanced PD.
It is also effective for treating RLS.
The review details its pharmacokinetic properties, metabolism, elimination, and potential drug interactions.

Conclusions:

Rotigotine is a versatile dopamine agonist with established efficacy for PD and RLS.
Its transdermal delivery offers a convenient dosing regimen.
Understanding its comprehensive profile supports its therapeutic application.